Abstract. Background: Gastric cancer is one of the most common malignant tumors worldwide, and the 2nd most common in China. The development of new agents for the treatment of advanced gastric cancer ...

DNA damage stress overload is a concept that describes the ability of a therapeutic regime to overwhelm the DNA damage response pathways in a cancer cell (1). This concept helps explain the efficacy ...

In 2003, Voskoglou-Nomikos (11) compared published drug activity for 31 cytotoxic cancer drugs where phase II trials, human xenograft, and mouse allograft responses were available for comparison for ...

Copper (Cu) is a cofactor of cytochrome c oxidase (CuCOX), indispensable for aerobic mitochondrial respiration. This study reveals that advanced clear cell renal cell carcinomas (ccRCC) accumulate Cu, ...

Abstract. The BCR-ABL1–negative myeloproliferative neoplasms (e.g., essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematologic malignancies that ...

Abstract. The large number of negative phase III trials in oncology over the last several years has renewed interest in refining phase II oncology clinical trials to maximize the chances of success in ...

Neuroblastoma, the most common extracranial solid tumor in children, accounts for approximately 15% of pediatric cancer–related mortality. While 90% of patients with neuroblastoma with low and ...

Abstract. Preclinical models have examined the pharmacologic and pharmacodynamic activities of an anti–vascular endothelial growth factor (VEGF) humanized, monoclonal antibody, bevacizumab, and/or its ...

AbstractEstrogen receptor–positive (ER+) breast cancer is not considered immunogenic and, to date, has been proven resistant to immunotherapy. Endocrine therapy remains the cornerstone of treatment ...

As clearly stated in the U.S. regulations [Title 21 Code Federal Regulations (CFR)], “Under current regulations, any use in the US of a drug product not previously authorized for marketing in the US ...

Cancer remains one of the leading causes of death globally (1, 2). Immunotherapy has opened a new era of cancer treatment; however, the therapeutic response to immune checkpoint inhibitors (ICI) in ...

During 20 years of follow-up, 1,915 prostate cancer and 166 fatal prostate cancer events were observed. Men in the top PRS quartile with a family history of prostate or breast cancer had the highest ...